A Look At Insider Reactions To Editas Medicine Inc. (EDIT)

As of Thursday close, Editas Medicine Inc.’s (NASDAQ:EDIT) stock was up $0.78, moving up 7.78 percent to $10.81. The average number of shares traded per day over the past five days has been 2,390,780 shares. 1 time new highs have been achieved over the past 5 days, with a -$3.75 fall in that time frame. In the last twenty days, the average volume was 1,832,435, while in the previous 50 days, it was 1,682,566.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Since last month, EDIT stock retreated -39.61%. Shares of the company fell to $9.71 on 05/12/22, the lowest level in the past month. A 52-week high of $73.03 was reached on 01/03/22 after having rallying from a 52-week low of $9.97. Since the beginning of this year, EDIT’s stock price has dropped by -59.28% or -$15.74, and marked a new high 1 time. However, the stock has declined by -85.20% since its 52-week high.

Editas Medicine Inc. (EDIT) last reported insider trading activity 4 days ago on May 09. Eaton Bruce, the EVP, CHIEF BUSINESS OFFICER of the company, disposed of 297 shares for $13.11 on May 09. It resulted in a $3,895 divestment by the insider. Eaton Bruce sold 1,258 shares at an average price of $19.64 on Apr 01. The insider now owns 66,841 shares following the transaction. On Mar 03, EVP, CHIEF FINANCIAL OFFICER ROBERTSON MICHELLE sold 767 shares at $17.33 apiece. The transaction was valued at $13,290.

Valuation Metrics

The stock’s beta is 2.05. Besides these, the trailing price-to-sales (P/S) ratio of 30.65, the price-to-book (PB) ratio of 1.44.

Financial Health

In the three months ended September 29, Editas Medicine Inc.’s quick ratio stood at 13.60, while its current ratio was 13.60, showing that the company is able to pay off its debt. Based on annual data, EDIT earned $218.69 million in gross profit and brought in $25.54 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -34.90%. Return on equity (ROE) for the past 12 months was -32.90%.

According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. EDIT’s revenue rose 3.99% to $12.47 million during the quarter, while net income inched up to $6.77 million. While analysts expected Editas Medicine Inc. to report -$0.82 quarterly earnings, the actual figure was -$0.57 per share, beating the consensus estimate by 30.50%. During the quarter, the company generated -$49.19 million in EBITDA. The liabilities of Editas Medicine Inc. were 110.35 million at the end of its most recent quarter ended September 29, and its total debt was $26.38 million. The value of shareholders’ equity is $68.64 million.

Technical Picture

This quick technical analysis looks at Editas Medicine Inc.’s (EDIT) price momentum. With a historical volatility rate of 153.75%, the RSI 9-day stood at 32.13% on 12 May.

With respect to its five-day moving average, the current Editas Medicine Inc. price is down by -25.76% percent or -$3.75. At present, EDIT shares trade -42.41% below its 20-day simple moving average and -63.82% percent below its 100-day simple moving average. However, the stock is currently trading approximately -36.97% below its SMA50 and -74.13% below its SMA200.

Stochastic coefficient K was 11.39% and Stochastic coefficient D was 9.94%, while ATR was 1.46. Given the Stochastic reading of 17.66% for the 14-day period, the RSI (14) reading has been calculated as 34.07%. As of today, the MACD Oscillator reading stands at -2.15, while the 14-day reading stands at -2.54.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles